Build Your Comparison

Side-by-side financial analysis
WAY logo
WAY
VEEV logo
VEEV
DOCS logo
DOCS
CRM logo
CRM
Try popular comparisons:

Stock Comparison

WAY vs VEEV vs DOCS vs CRM

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
WAY
Waystar Holding Corp.

Information Technology Services

TechnologyNASDAQ • US
Market Cap$3.60B
5Y Perf.-12.8%
VEEV
Veeva Systems Inc.

Medical - Healthcare Information Services

HealthcareNYSE • US
Market Cap$25.92B
5Y Perf.-12.8%
DOCS
Doximity, Inc.

Medical - Healthcare Information Services

HealthcareNYSE • US
Market Cap$3.75B
5Y Perf.-28.4%
CRM
Salesforce, Inc.

Software - Application

TechnologyNYSE • US
Market Cap$135.86B
5Y Perf.-35.5%

WAY vs VEEV vs DOCS vs CRM — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
WAY logoWAY
VEEV logoVEEV
DOCS logoDOCS
CRM logoCRM
IndustryInformation Technology ServicesMedical - Healthcare Information ServicesMedical - Healthcare Information ServicesSoftware - Application
Market Cap$3.60B$25.92B$3.75B$135.86B
Revenue (TTM)$1.16B$3.32B$645M$42.83B
Net Income (TTM)$126M$942M$196M$8.02B
Gross Margin65.2%75.0%89.1%77.6%
Operating Margin24.3%28.8%33.3%21.9%
Forward P/E11.4x17.6x14.0x14.1x
Total Debt$1.50B$96M$10M$17.18B
Cash & Equiv.$61M$1.42B$219M$7.33B

WAY vs VEEV vs DOCS vs CRMLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

WAY
VEEV
DOCS
CRM
StockJun 24Jun 26Return
Waystar Holding Cor… (WAY)10087.2-12.8%
Veeva Systems Inc. (VEEV)10087.2-12.8%
Doximity, Inc. (DOCS)10071.6-28.4%
Salesforce, Inc. (CRM)10064.5-35.5%

Price return only. Dividends and distributions are not included.

Quick Verdict: WAY vs VEEV vs DOCS vs CRM

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: CRM leads in 3 of 7 categories, making it the strongest pick for capital preservation and lower volatility and dividend income and shareholder returns. Waystar Holding Corp. is the stronger pick specifically for growth and revenue expansion and valuation and capital efficiency. DOCS also leads in specific categories worth noting. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
🥇CRM emerged as the overall leader. Track its performance:
WAY
Waystar Holding Corp.
The Growth Play

WAY is the #2 pick in this set and the best alternative if growth exposure is your priority.

  • Rev growth 16.5%, EPS growth 5.7%, 3Y rev CAGR 16.0%
  • 16.5% revenue growth vs CRM's 9.6%
  • Lower P/E (11.4x vs 17.6x)
Best for: growth exposure
VEEV
Veeva Systems Inc.
The Long-Run Compounder

VEEV is the clearest fit if your priority is long-term compounding and sleep-well-at-night.

  • 367.2% 10Y total return vs CRM's 108.7%
  • Lower volatility, beta 0.69, Low D/E 1.3%, current ratio 4.89x
  • Beta 0.69, current ratio 4.89x
Best for: long-term compounding and sleep-well-at-night
DOCS
Doximity, Inc.
The Value Pick

DOCS is the clearest fit if your priority is valuation efficiency.

  • PEG 0.27 vs CRM's 1.15
  • 30.4% margin vs WAY's 10.9%
  • 16.5% ROA vs WAY's 2.4%, ROIC 19.8% vs 4.2%
Best for: valuation efficiency
CRM
Salesforce, Inc.
The Income Pick

CRM carries the broadest edge in this set and is the clearest fit for income & stability.

  • Dividend streak 2 yrs, beta 0.64, yield 1.0%
  • Beta 0.64 vs WAY's 0.84, lower leverage
  • 1.0% yield; 2-year raise streak; the other 3 pay no meaningful dividend
  • -37.1% vs DOCS's -64.8%
Best for: income & stability
See the full category breakdown
CategoryWinnerWhy
GrowthWAY logoWAY16.5% revenue growth vs CRM's 9.6%
ValueWAY logoWAYLower P/E (11.4x vs 17.6x)
Quality / MarginsDOCS logoDOCS30.4% margin vs WAY's 10.9%
Stability / SafetyCRM logoCRMBeta 0.64 vs WAY's 0.84, lower leverage
DividendsCRM logoCRM1.0% yield; 2-year raise streak; the other 3 pay no meaningful dividend
Momentum (1Y)CRM logoCRM-37.1% vs DOCS's -64.8%
Efficiency (ROA)DOCS logoDOCS16.5% ROA vs WAY's 2.4%, ROIC 19.8% vs 4.2%

WAY vs VEEV vs DOCS vs CRM — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

Discover the Cloud Software Stocks Theme

These companies are key players in the Cloud Software Stocks ecosystem. See how they stack up against the rest of the sector.

Explore Theme
WAYWaystar Holding Corp.
FY 2025
Subscription and Circulation
100.0%$558M
VEEVVeeva Systems Inc.
FY 2026
Subscription Services Veeva Commercial Cloud
86.9%$1.3B
Professional Services Veeva Commercial Cloud
13.1%$189M
DOCSDoximity, Inc.
FY 2026
Subscription
94.3%$608M
Service, Other
5.7%$36M
CRMSalesforce, Inc.
FY 2026
Service Cloud
23.6%$9.8B
Sales Cloud
21.7%$9.0B
Salesforce Platform and Other
21.4%$8.9B
Integration And Analytics
15.0%$6.2B
Marketing and Commerce Cloud
13.1%$5.4B
Professional Services and Other
5.1%$2.1B

WAY vs VEEV vs DOCS vs CRM — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLWAYLAGGINGVEEV

Income & Cash Flow (Last 12 Months)

DOCS leads this category, winning 3 of 6 comparable metrics.

CRM is the larger business by revenue, generating $42.8B annually — 66.4x DOCS's $645M. DOCS is the more profitable business, keeping 30.4% of every revenue dollar as net income compared to WAY's 10.9%. On growth, WAY holds the edge at +22.4% YoY revenue growth, suggesting stronger near-term business momentum.

MetricWAY logoWAYWaystar Holding C…VEEV logoVEEVVeeva Systems Inc.DOCS logoDOCSDoximity, Inc.CRM logoCRMSalesforce, Inc.
RevenueTrailing 12 months$1.2B$3.3B$645M$42.8B
EBITDAEarnings before interest/tax$430M$1.1B$227M$12.2B
Net IncomeAfter-tax profit$126M$942M$196M$8.0B
Free Cash FlowCash after capex$294M$518M$215M$14.7B
Gross MarginGross profit ÷ Revenue+65.2%+75.0%+89.1%+77.6%
Operating MarginEBIT ÷ Revenue+24.3%+28.8%+33.3%+21.9%
Net MarginNet income ÷ Revenue+10.9%+28.4%+30.4%+18.7%
FCF MarginFCF ÷ Revenue+25.4%+15.6%+33.3%+34.2%
Rev. Growth (YoY)Latest quarter vs prior year+22.4%+16.3%+5.1%+13.3%
EPS Growth (YoY)Latest quarter vs prior year+37.5%+14.6%-67.7%+52.2%
DOCS leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

WAY leads this category, winning 3 of 7 comparable metrics.

At 20.4x trailing earnings, DOCS trades at a 33% valuation discount to WAY's 30.7x P/E. Adjusting for growth (PEG ratio), DOCS offers better value at 0.39x vs CRM's 1.74x — a lower PEG means you pay less per unit of expected earnings growth.

MetricWAY logoWAYWaystar Holding C…VEEV logoVEEVVeeva Systems Inc.DOCS logoDOCSDoximity, Inc.CRM logoCRMSalesforce, Inc.
Market CapShares × price$3.6B$25.9B$3.7B$135.9B
Enterprise ValueMkt cap + debt − cash$5.0B$24.6B$3.5B$145.7B
Trailing P/EPrice ÷ TTM EPS30.74x29.33x20.45x21.27x
Forward P/EPrice ÷ next-FY EPS est.11.42x17.61x13.99x14.09x
PEG RatioP/E ÷ EPS growth rate1.61x0.39x1.74x
EV / EBITDAEnterprise value multiple12.39x20.59x16.47x11.61x
Price / SalesMarket cap ÷ Revenue3.27x8.11x5.81x3.27x
Price / BookPrice ÷ Book value/share0.95x3.69x4.20x2.68x
Price / FCFMarket cap ÷ FCF12.70x18.70x9.43x
WAY leads this category, winning 3 of 7 comparable metrics.

Profitability & Efficiency

DOCS leads this category, winning 6 of 9 comparable metrics.

DOCS delivers a 19.4% return on equity — every $100 of shareholder capital generates $19 in annual profit, vs $4 for WAY. DOCS carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to WAY's 0.39x. On the Piotroski fundamental quality scale (0–9), CRM scores 7/9 vs WAY's 5/9, reflecting strong financial health.

MetricWAY logoWAYWaystar Holding C…VEEV logoVEEVVeeva Systems Inc.DOCS logoDOCSDoximity, Inc.CRM logoCRMSalesforce, Inc.
ROE (TTM)Return on equity+3.5%+13.4%+19.4%+14.9%
ROA (TTM)Return on assets+2.4%+11.0%+16.5%+7.8%
ROICReturn on invested capital+4.2%+12.9%+19.8%+10.1%
ROCEReturn on capital employed+5.2%+13.8%+20.7%+11.9%
Piotroski ScoreFundamental quality 0–95667
Debt / EquityFinancial leverage0.39x0.01x0.01x0.29x
Net DebtTotal debt minus cash$1.4B-$1.3B-$209M$9.8B
Cash & Equiv.Liquid assets$61M$1.4B$219M$7.3B
Total DebtShort + long-term debt$1.5B$96M$10M$17.2B
Interest CoverageEBIT ÷ Interest expense3.51x21.32x
DOCS leads this category, winning 6 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

WAY leads this category, winning 3 of 6 comparable metrics.

A $10,000 investment in WAY five years ago would be worth $9,058 today (with dividends reinvested), compared to $3,781 for DOCS. Over the past 12 months, CRM leads with a -37.1% total return vs DOCS's -64.8%. The 3-year compound annual growth rate (CAGR) favors WAY at -3.2% vs DOCS's -15.0% — a key indicator of consistent wealth creation.

MetricWAY logoWAYWaystar Holding C…VEEV logoVEEVVeeva Systems Inc.DOCS logoDOCSDoximity, Inc.CRM logoCRMSalesforce, Inc.
YTD ReturnYear-to-date-40.2%-27.3%-53.7%-34.2%
1-Year ReturnPast 12 months-52.6%-43.5%-64.8%-37.1%
3-Year ReturnCumulative with dividends-9.4%-16.2%-38.7%-20.4%
5-Year ReturnCumulative with dividends-9.4%-47.5%-62.2%-31.0%
10-Year ReturnCumulative with dividends-9.4%+367.2%-62.2%+108.7%
CAGR (3Y)Annualised 3-year return-3.2%-5.7%-15.0%-7.3%
WAY leads this category, winning 3 of 6 comparable metrics.

Risk & Volatility

CRM leads this category, winning 2 of 2 comparable metrics.

CRM is the less volatile stock with a 0.64 beta — it tends to amplify market swings less than WAY's 0.84 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CRM currently trades 59.9% from its 52-week high vs DOCS's 26.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricWAY logoWAYWaystar Holding C…VEEV logoVEEVVeeva Systems Inc.DOCS logoDOCSDoximity, Inc.CRM logoCRMSalesforce, Inc.
Beta (5Y)Sensitivity to S&P 5000.84x0.69x0.75x0.64x
52-Week HighHighest price in past year$41.47$310.50$76.51$276.80
52-Week LowLowest price in past year$17.89$148.05$17.16$161.40
% of 52W HighCurrent price vs 52-week peak+45.2%+51.4%+26.2%+59.9%
RSI (14)Momentum oscillator 0–10040.343.840.738.9
Avg Volume (50D)Average daily shares traded2.4M2.3M3.9M12.5M
CRM leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

CRM leads this category, winning 1 of 1 comparable metric.

Analyst consensus: WAY as "Buy", VEEV as "Buy", DOCS as "Hold", CRM as "Buy". Consensus price targets imply 90.0% upside for WAY (target: $36) vs 47.1% for DOCS (target: $29). CRM is the only dividend payer here at 1.00% yield — a key consideration for income-focused portfolios.

MetricWAY logoWAYWaystar Holding C…VEEV logoVEEVVeeva Systems Inc.DOCS logoDOCSDoximity, Inc.CRM logoCRMSalesforce, Inc.
Analyst RatingConsensus buy/hold/sellBuyBuyHoldBuy
Price TargetConsensus 12-month target$35.62$235.38$29.47$265.75
# AnalystsCovering analysts17432397
Dividend YieldAnnual dividend ÷ price+1.0%
Dividend StreakConsecutive years of raises02
Dividend / ShareAnnual DPS$1.66
Buyback YieldShare repurchases ÷ mkt cap0.0%+0.7%+11.5%+9.3%
CRM leads this category, winning 1 of 1 comparable metric.
Key Takeaway

DOCS leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). WAY leads in 2 (Valuation Metrics, Total Returns).

Best OverallWaystar Holding Corp. (WAY)Leads 2 of 6 categories
Loading custom metrics...

WAY vs VEEV vs DOCS vs CRM: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is WAY or VEEV or DOCS or CRM a better buy right now?

For growth investors, Waystar Holding Corp.

(WAY) is the stronger pick with 16. 5% revenue growth year-over-year, versus 9. 6% for Salesforce, Inc. (CRM). Doximity, Inc. (DOCS) offers the better valuation at 20. 4x trailing P/E (14. 0x forward), making it the more compelling value choice. Analysts rate Waystar Holding Corp. (WAY) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — WAY or VEEV or DOCS or CRM?

On trailing P/E, Doximity, Inc.

(DOCS) is the cheapest at 20. 4x versus Waystar Holding Corp. at 30. 7x. On forward P/E, Waystar Holding Corp. is actually cheaper at 11. 4x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Doximity, Inc. wins at 0. 27x versus Salesforce, Inc. 's 1. 15x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

03

Which is the better long-term investment — WAY or VEEV or DOCS or CRM?

Over the past 5 years, Waystar Holding Corp.

(WAY) delivered a total return of -9. 4%, compared to -62. 2% for Doximity, Inc. (DOCS). Over 10 years, the gap is even starker: VEEV returned +367. 2% versus DOCS's -62. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — WAY or VEEV or DOCS or CRM?

By beta (market sensitivity over 5 years), Salesforce, Inc.

(CRM) is the lower-risk stock at 0. 64β versus Waystar Holding Corp. 's 0. 84β — meaning WAY is approximately 32% more volatile than CRM relative to the S&P 500. On balance sheet safety, Doximity, Inc. (DOCS) carries a lower debt/equity ratio of 1% versus 39% for Waystar Holding Corp. — giving it more financial flexibility in a downturn.

05

Which is growing faster — WAY or VEEV or DOCS or CRM?

By revenue growth (latest reported year), Waystar Holding Corp.

(WAY) is pulling ahead at 16. 5% versus 9. 6% for Salesforce, Inc. (CRM). On earnings-per-share growth, the picture is similar: Waystar Holding Corp. grew EPS 569. 2% year-over-year, compared to -11. 7% for Doximity, Inc.. Over a 3-year CAGR, WAY leads at 16. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — WAY or VEEV or DOCS or CRM?

Doximity, Inc.

(DOCS) is the more profitable company, earning 30. 4% net margin versus 10. 2% for Waystar Holding Corp. — meaning it keeps 30. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DOCS leads at 33. 3% versus 21. 5% for CRM. At the gross margin level — before operating expenses — DOCS leads at 89. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is WAY or VEEV or DOCS or CRM more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Doximity, Inc. (DOCS) is the more undervalued stock at a PEG of 0. 27x versus Salesforce, Inc. 's 1. 15x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Waystar Holding Corp. (WAY) trades at 11. 4x forward P/E versus 17. 6x for Veeva Systems Inc. — 6. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for WAY: 90. 0% to $35. 62.

08

Which pays a better dividend — WAY or VEEV or DOCS or CRM?

In this comparison, CRM (1.

0% yield) pays a dividend. WAY, VEEV, DOCS do not pay a meaningful dividend and should not be held primarily for income.

09

Is WAY or VEEV or DOCS or CRM better for a retirement portfolio?

For long-horizon retirement investors, Salesforce, Inc.

(CRM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 64), 1. 0% yield, +108. 7% 10Y return). Both have compounded well over 10 years (CRM: +108. 7%, WAY: -9. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between WAY and VEEV and DOCS and CRM?

These companies operate in different sectors (WAY (Technology) and VEEV (Healthcare) and DOCS (Healthcare) and CRM (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: WAY is a small-cap high-growth stock; VEEV is a mid-cap high-growth stock; DOCS is a small-cap quality compounder stock; CRM is a mid-cap quality compounder stock. CRM pays a dividend while WAY, VEEV, DOCS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.